Health promotion and chronic disease prevention in Canada : research, policy and practice
-
Health Promot Chronic Dis Prev Can · Jun 2018
ReviewThe opioid crisis in Canada: a national perspective.
This review provides a national summary of what is currently known about the Canadian opioid crisis with respect to opioid-related deaths and harms and potential risk factors as of December 2017. ⋯ This report identifies gaps in evidence and areas for further investigation to improve our understanding of the national opioid crisis. The Public Health Agency of Canada will continue to work closely with the provinces, territories and national partners to further refine and standardize national data collection, conduct special studies and expand information-sharing to improve the evidence needed to inform public health action and prevent opioid-related deaths and harms.
-
Health Promot Chronic Dis Prev Can · Jun 2018
At-a-glance - Lessons learned from launching the Manitoba Take-Home Naloxone Program.
The Government of Manitoba launched the provincial Take-Home Naloxone Program in January 2017. By the end of September 2017, there were over 60 sites operating in Manitoba. ⋯ Fentanyl and carfentanil were the most common substances reported during overdose events. Take-Home Naloxone Program data provide important information about the unique context of the opioid crisis in Manitoba.
-
Health Promot Chronic Dis Prev Can · Jun 2018
At-a-glance - Hospitalizations and emergency department visits due to opioid poisoning in Canada.
The rise in opioid-related harms is an issue of increasing public health importance in Canada. This analysis used data from the Hospital Morbidity Database and the National Ambulatory Care Reporting System to determine the number of opioid poisoning hospitalizations and emergency department visits in Canada. ⋯ Emergency department visits due to opioid poisoning have also increased in Alberta and Ontario, the two provinces that collect emergency department data at the level of detail required for this analysis. These findings highlight the importance of pan- Canadian surveillance of opioid-related harms, as well as the need for evidence-based policies to help reduce these harms.